We are happy to announce that on the 22nd of November 2022 One-carbon Therapeutics received confirmation from the US patent office that a key patent covering the company’s leading drug candidate for the treatment of cancers, inflammation, autoimmune diseases has been granted. The granting of this patent establishes our strong IP portfolio and lays the foundation for further clinical development for different indications with great unmet medical needs.
We are presenting our novel MTHFD1/2 inhibitor at the DDR inhibitor summit
We are presenting our data at the DDR inhibitor summit,
